SCHEMBL29796282

SCHEMBL29796282

CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OC[C@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1

nearest known ligand 0.87

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 18/20 0.87
▸ BCL2L1 Q07817 2/20 0.79
▸ NSD2 O96028 1/20 0.78
▸ ADORA3 P0DMS8 1/20 0.78
▸ CYP2C9 P11712 1/20 0.78
▸ ADRA2C P18825 1/20 0.78
▸ SLC6A2 P23975 1/20 0.78
▸ BID P55957 1/20 0.78
▸ SLC6A3 Q01959 1/20 0.78
▸ MCL1 Q07820 1/20 0.78
▸ ASPH Q12797 1/20 0.78
▸ BCL2L2 Q92843 1/20 0.78
▸ BAD Q92934 1/20 0.78
▸ NSD1 Q96L73 1/20 0.78
▸ NSD3 Q9BZ95 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1699781 1.00 BCL2 (0.87) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL1701502 1.00 BCL2 (0.87) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL1701434 1.00 BCL2 (0.87) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL29796440 1.00 BCL2 (0.87) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL30314021 1.00 BCL2 (0.87) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL16037497 0.93 BCL2 (0.90) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL30298472 0.93 BCL2 (0.90) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL30314032 0.93 BCL2 (0.90) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL16038722 0.93 BCL2 (0.90) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL1699850 0.93 BCL2 (0.90) BCL2BCL2L1NSD2ADORA3CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4682148-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2026-01-21 — — EP disclosed
EP-4474383-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2024-12-11 — — EP disclosed
CN-116635062-A Combination therapy using Chimeric Antigen Receptor (CAR) expressing cells 诺华股份有限公司 2023-08-22 — — CN disclosed
EP-4218731-A2 MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT AbbVie Ireland Unlimited Company (IE) 2023-08-02 — — EP disclosed
CN-114786679-A Combination therapy with Vernetork and TIM-3 inhibitors 诺华股份有限公司 2022-07-22 — — CN disclosed
CN-114786680-A TIM-3 inhibitors and uses thereof 诺华股份有限公司 2022-07-22 — — CN disclosed
Send feedback